To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the vaunted, 30-company Dow Jones Industrial Average that year. Yet, if the ...

Here's the skinny on that quarter and whether the rest of the year will be healthy enough to rank the company's stock as a buy. To give some idea of the sheer size of Johnson & Johnson ...

Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...

We recently published a list of 12 Best Defensive Stocks To Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best defensive ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other ...

UPS and JNJ present strong dividends and attractive valuations. See why these durable companies are great for a buy-and-hold ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Johnson & Johnson was founded over 125 years ... And at the tail end of 2020, a $6.5 billion deal to buy Momenta meant that J&J added potential inflammatory disease blockbuster nipocalimab to ...